Dociparstat sodium

Drug Profile

Dociparstat sodium

Alternative Names: CX-01; ODSH; PGX-100; PGX-ODSH-2013-AML-1

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator ParinGenix
  • Developer Cantex Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Heparins; Ischaemic heart disorder therapies
  • Mechanism of Action Cathepsin G inhibitors; Leucocyte elastase inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Pancreatic cancer
  • Phase I Thrombocytopenia
  • Clinical Phase Unknown Lung cancer; Solid tumours
  • Discontinued Acute coronary syndromes; Chronic obstructive pulmonary disease; Myocardial infarction; Reperfusion injury

Most Recent Events

  • 08 Feb 2017 Chemical structure information added
  • 13 Dec 2016 Cantex Pharmaceuticals plans a phase I trial for Acute myeloid leukaemia and Myelodysplastic syndromes in USA (NCT02995655)
  • 03 Dec 2016 Efficacy and adverse event data from a phase I trial in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top